The presentation will be available on the Rectify website at https://rectifypharma.com/publications/.

Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...

Dr Falk Pharma, a research-based pharmaceutical company specialising in digestive and metabolic medicine, has announced ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

A copy of the R&D Day presentation can be found here. About Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis (PSC) is a rare, progressive, cholestatic, immune‐mediated disease of ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...

A copy of the R&D Day presentation can be found here. Primary Sclerosing Cholangitis (PSC) is a rare, progressive, cholestatic, immune‐mediated disease of the bile ducts. Bile ducts carry the ...

Objectives: To describe the occurrence of secondary sclerosing cholangitis in critically ill patients (SC-CIP) with febrile infection-related epilepsy syndrome (FIRES). Methods: Monocentric ...

A group dedicated to electing young progressives co-founded by David Hogg, the vice chair of the Democratic National Committee, is launching a $20 million effort to primary “out-of-touch, ...